EP1363638A2 - Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes - Google Patents
Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodesInfo
- Publication number
- EP1363638A2 EP1363638A2 EP02714918A EP02714918A EP1363638A2 EP 1363638 A2 EP1363638 A2 EP 1363638A2 EP 02714918 A EP02714918 A EP 02714918A EP 02714918 A EP02714918 A EP 02714918A EP 1363638 A2 EP1363638 A2 EP 1363638A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- branched
- straight chained
- alkyl
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- Depression is the most common of mental disorders and yet is often underdiagnosed and undertreated, inflicting substantial morbidity and psychosocial impairment on its sufferers. Depression is mainly characterized by sadness, flatness, loss of feeling, anhedonia (lack of pleasure) , tearfulness, agitation or retardation, thoughts of guilt, and worthlessness; in severe cases, suicide, hallucinations and delusions .
- Depression can be mainly categorized into bipolar disorders, identifying wide swings of mood; major depressive illness, marked by severe depressive symptoms but without manic swings; and less defined milder forms of bipolar and major depression that fall short of the specific diagnostic criteria e.g. dysthymic disorder (formerly called depressive neurosis) .
- the symptomatology and diagnostic criteria for depression are set out in the DS IV guidelines (American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders) .
- DS IV guidelines American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders
- depressive illness a markedly gloomy mood in which there is a loss of interest in life, and general feelings of hopelessness and worthlessness.
- Depressive symptoms range in severity from mild mood swings to severe delusions about self-worth, accomplishments, and the future.
- the "blackness" of the presentation in the depressed patient is most often accompanied by severe motor retardation with profound sleep and appetite disturbance and suicidal ideation. Furthermore, depressive illness can also present in a highly anxious or agitated state.
- the degree to which the underlying brain mechanisms in anxiety and depression differ or overlap remains unknown. The fact, however, that to some extent the same neurotransmitter systems are involved in depression and anxiety does not mean that the mechanisms are identical. However, the majority of people in an episode of either depression or anxiety also meet criteria for at least one other psychiatric disorder. But by far the strongest comorbidities in both cases are between depression and anxiety disorders. Therefore, it is now becoming common clinical practice to treat both indications with antidepressants such as SSRIs .
- the key clinical features of anxiety disorders relate to various combinations of psychological and physical manifestations of anxiety, not attributable to real danger and occurring either in attacks (panic disorder - PD) or as a persisting state (generalized anxiety disorder -GAD) . Other neurotic features may be present (obsessional or hysterical symptoms) but do not dominate the clinical picture.
- TCAs tricylic antidepressants
- SSRIs selective serotonin re-uptake inhibitors
- MAOIs monoamine oxidase inhibitors
- This theory postulates that a certain level of amines and/or receptor sensitivity to catecholamines functions to generate a normal mood.
- a receptor insensitivity, a depletion of monoamines, or a decrease in their release, synthesis or storage have been postulated to lead to depression.
- a variety of pharmacological agents have been employed to treat depression based on the catecholamine-indolamine hypothesis of depression.
- Drugs used to treat depression include MAOIs, atypical antipsychotics, lithium, TCAs, and SSRIs.
- off-label agents such as antiepileptics are used to treat depression in treatment-resistant patients.
- Tricyclic antidepressants are about equal to SSRIs in effectiveness against depression thus providing supporting evidence for the catecholamine-indolamine hypothesis of depression.
- SSRIs have largely displaced TCAs because of side effects associated with TCAs and the need to monitor EKG and plasma drug concentration.
- Adverse effects on sexual function primarily anorgasmia and delayed ejaculation, have been consistently reported.
- Other, common side-effects include sleep disorders, yawning, weight changes, suicidal ideation and extrapyramidal-like side-effects such as dystonic reactions.
- OCD obsessive compulsive disorder
- GAD generalized anxiety disorder
- PD panic disorder
- the rat Forced Swim Test is a behavioral test that is used to screen compounds for antidepressant efficacy (Porsolt et al . , 1977, 1978; Porsolt, 1981). This test is widely used as it is reliable across laboratories, relatively easy to perform and is sensitive to the effects of some of the major classes of antidepressant drugs, including TCAs and MAOIs, and various atypical antidepressants. Furthermore, this test is relatively selective for antidepressant drugs, as few psychoactive drugs produce similar behavioral actions in the FST.
- animals are placed in a cylinder of water, from which there is no escape, for an extended period of time.
- animals will display a range of behaviors such as immobility, climbing, swimming, and diving, with immobility being predominant after several minutes of immersion in the water. Consequently, many past studies have only measured or scored immobility after the administration of the test agent .
- this method does not score any other active behaviors that may be produced by potential antidepressants. Thus, if a particular class of antidepressant were to have very little effect on immobility, yet produce characteristic behaviors during the FST, these behaviors would not be scored and the conclusion would be that the compound in question does not possess antidepressant action.
- SIT Social Interaction Test
- rats previously housed singly are placed in a familiar, dimly lit, test arena with weight- matched, novel partners.
- the principal anxiogenic stimulus under these conditions is the partner novelty, which involves an unconditioned response to a potential threat.
- the following behaviors are scored as active social interaction: grooming, sniffing, biting, boxing, wrestling, following, crawling over and crawling under.
- the social interaction test can distinguish anxiolytics from antidepressants, antipsychotics, analeptics and sedative agents (File, 1985; Guy and Gardner, 1985) .
- This test can detect anxiolytic agents such as the benzodiazepines (File and Hyde, 1978; File and Hyde, 1979; File, 1980), in addition to non-benzodiazepines, including paroxetine and other SSRIs (Lightowler, et al . , 1994).
- the social interaction test can detect anxiogenic agents, including the inverse benzodiazepine receptor agonists (File, et al., 1982; File and Pellow, 1983; File and Pellow, 1984; File , 1985 ) .
- the synthesis of novel pyrimidines which bind selectively to the cloned human GAL3 receptor, compared to other cloned human G- protein coupled receptors, as measured in in vi tro assays is disclosed.
- the synthesis of indolones which bind selectively to the cloned human GAL3 receptor, compared to other cloned human G-protein coupled receptors, as measured in in vi tro assays is disclosed.
- the in vi tro receptor assays described hereinafter were performed using various cultured cell lines, each transfected with and expressing only a single galanin-type receptor.
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- X is; NR ⁇ R ⁇ 2 ;
- Rn is H, straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , aryl, or aryl (C ⁇ -C 6 ) alkyl; wherein R 12 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or -(CH 2 ) ra -Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl , C 3 -C ⁇ 0 cycloalkyl, heteroaryl, aryl, aryl(C ⁇ - C 6 ) alkyl, Q_ ⁇ or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R ⁇ g)-Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 wherein R 4 is H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R i4 is H, straight chained or branched C ⁇ -C 3 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R i9 ) 2 ) m -Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl
- R ⁇ S is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ! -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i7 is independently H; -0R 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR21, -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2 , -COOR21, straight chained or branched C x -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl , straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ,-
- R ⁇ 8 is straight chained or branched C ⁇ -C 3 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R ⁇ 9 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 2 o is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -CI, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 2 ⁇ , -OCOR 21 , -COR 21 , -NCOR 21 , -N(R 2 ⁇ ) a , - CON(R 2 ⁇ ) 2 , or -COOR21; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2 ⁇ is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -
- each R 22 is independently H, F, CI or C ! -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- U is 0, -NR ⁇ 6 , S, C(R 17 ) 2 , or -NS0 2 R 5 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 7 cyclic ether, C-C 7 cyclic thioether, aryl, or heteroaryl; or
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, -F, -CI, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- X is NRuR ⁇ 2 ;
- R u is H, straight chained or branched C x -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , aryl or aryl (C-.-C 6 ) alkyl;
- R ⁇ 2 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R i3 is a bicyclic alkyl ring system, aryl 'or aryl (Ci-Cs) alkyl;
- Y is NR ⁇ 4 R 15 ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl , or ( C (R 19 ) 2 ) m -Z ;
- R ⁇ 5 is straight chained or branched C 3 -C 5 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C e cycloalkyl, or (C (R 19 ) 2 ) ra -Z;
- U is 0, -NR ⁇ 6/ S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ S ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 1S is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched 2 - ⁇ alkynyl, C 3 -C ⁇ cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ; wherein each R x7 is independently H; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , -CON(R 21 ) 2 , -COOR 2 ⁇ , straight chained or branched Q L -C 7 alkyl, straight chained or branched C
- R ⁇ 8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R ⁇ 9 is independently H, or straight chained or branched C ⁇ -C e alkyl
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -CI, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 21 , -NCOR 21 , -N (R 2 ⁇ ) 2 , - CON(R 2 ⁇ ) 2 , or -COOR 2 ⁇ ; aryl or heteroaryl; or two R 2 o groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2 ⁇ is independently -H; straight chained or branched C-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (Ci- C s ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive; wherein p is an integer from 0 to 2 inclusive;
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, -F, -CI, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R i3 is an aryl, adamantyl, noradamantyl , C 3 -C ⁇ 0 cycloalkyl, heteroaryl, Q or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C ⁇ 0 straight chained or branched alkyl, aryl, heteroaryl, or N(R i9 ) -Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ; wherein R 4 is -H; straight chained or branched C ⁇ -C ⁇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- Y is NR ⁇ 4 R ⁇ S ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl
- R ⁇ S is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- U is O, -NR 1S , S, C(R 17 ) 2 , or -NS0 2 R ⁇ e ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl; wherein R ⁇ 6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl , straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i7 is independently H; -OR 2i , -OC0R 2i , -COR 21 , -NCOR21, -N(R 2 ⁇ ) 2 / -C0N(R 21 ) 2 , -COOR21, straight chained or branched C x -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R ⁇ 8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 19 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 2 o is independently -H; straight chained or branched C x -C alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -CI, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 2i , -OCOR 2 ⁇ , -COR 21 , -NCOR 2i , -N(R 2 ⁇ ) 2 , - CON(R 2 ⁇ ) 2 , or -COOR21; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C ⁇ - C 6 ) alkyl;
- each R 22 is independently H, F, CI or C ⁇ -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the present invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, -F, -CI, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (Ci-Cs) alkyl;
- Y is NR 14 R ⁇ 5 ;
- R 14 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- R ⁇ 5 is (C (R 19 ) 2 ) m -N(R ⁇ 6 ) 2 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- R 1S is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 1 is independently H; -0R 2i , -OC0R 2 ⁇ , -COR 2 ⁇ , -NCOR 21 , -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2 , -COOR21, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- each R 19 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 21 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C ⁇ C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- q is an integer from 2 to 4 inclusive;
- the present invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, -F, -CI, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- X is; NRnR ⁇ 2 ;
- R n is H, straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , aryl, or aryl (C ⁇ -C 3 ) alkyl;
- R i2 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R i3 is a bicyclic alkyl ring system, adamantyl, noradamantyl , C 3 -C ⁇ 0 cycloalkyl, heteroaryl, aryl, aryl (C x - C 6 ) alkyl , & or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C ⁇ 0 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )-Z;
- each J is independently 0, S, C(R 22 ) 2 or NR 4 ;
- R is H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R 14 is H, straight chained or branched C x -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R x9 ) 2 ) m -Z;
- R iS is straight chained or branched C 3 -C 3 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, (C (R 19 ) 2 ) m N (R 16 ) 2 or
- R ⁇ S is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monof luoroalkyl, straight chained or branched C ⁇ -C polyfluoroalkyl, straight chained or branched C 2 -C ⁇ alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 17 is independently H; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR 21 , -N(R 2i ) 2 , -CON(R 21 ) 2 , -COOR21, straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R ⁇ 8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) ra -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i9 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 2 o is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -CI, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 2 ⁇ , -OCOR 2 i, -C0R 21 , -NCOR 21 , -N(R 21 ) 2 , - CON(R 2 ⁇ ) 2 , or -COOR21; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl (Cx- C 6 ) alkyl;
- each R 22 is independently H, F, CI or C ⁇ -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive; wherein each n is an integer from 1 to 4 inclusive;
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- U is 0, -NR ⁇ 6 , S, C(R 17 ) 2 , or -NS0 2 R ⁇ e ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy; wherein X is NRnR ⁇ 2 ;
- Ru is H, straight chained or branched C x -C 7 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , aryl or aryl (C ⁇ -C 6 ) alkyl;
- R 12 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (Ci-Cg) alkyl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C(R ⁇ 9 ) 2 ) m -Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- U is 0, -NR i6 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ g;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ; wherein each R 17 is independently H; -OR 21 , -OCOR 1 , -COR 21 , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 / -CON(R 2 ⁇ ) 2 , -COOR 2 ⁇ , straight chained or branched C 1 -C 7 alkyl, straight chained or branched C x -C 7 mono
- polyfluoroalkyl straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R ⁇ 8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) ra -CH 3 ;
- each R i9 is independently H, or straight chained or branched C ⁇ -C 3 alkyl
- each R 0 is independently -H; straight chained or branched C ⁇ C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -CI, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 2 ⁇ , -OCOR 21 , -C0R 21 , -NCOR2 1 , -N(R 21 ) 2 , - CON(R 2 ⁇ ) 2 , or -COOR21; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2i is independently -H; straight chained or branched C1-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (Ci- C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive; wherein p is an integer from 0 to 2 inclusive;
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, -F, -CI, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R ⁇ 3 is an aryl, adamantyl, noradamantyl, C 3 -C ⁇ 0 cycloalkyl, heteroaryl, Qi or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C ⁇ o straight chained or branched alkyl, aryl, heteroaryl, or N(R ⁇ 9 ) -Z;
- each J is independently 0, S, C(R 22 ) 2 or NR 4 ;
- R 4 is -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl; wherein Y is NR ⁇ 4 R ⁇ 5 ;
- R 14 is H, straight chained or branched £ ⁇ -ds alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- U is O, -NR ⁇ 6 , S, C(R ⁇ ? ) 2 , or -NS0 2 R ⁇ 5 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- R i5 is straight chained or branched C-C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C1-C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i7 is independently H; -OR ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR 2 ⁇ , -N(R 2i ) 2 , -CON(R 2 ⁇ ) 2 , -COOR 2i , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R ⁇ 8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i9 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C-C alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -CI, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 21 , -OCOR 2 ⁇ , -COR 21f -NCOR 2 ⁇ , -N (R 21 ) 2 , - C0N(R 2 ⁇ ) 2 , or -COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2 ⁇ is independently -H; straight chained or branched C1-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C ⁇ - C 6 ) alkyl; wherein each R 22 is independently H, F, Cl or C ⁇ -C 4 straight chained or branched alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R i3 is a bicyclic alkyl ring system, aryl or aryl (Ci-Cg) alkyl ;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl , (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl , or (C (R 19 ) 2 ) m -Z ;
- R ⁇ 5 is (C (R X9 ) 2 ) m -N (R 16 ) 2 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- R i6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C 1 -C7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 17 is independently H; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR2 1 , -N(R 2i ) 2 , -CON(R 2 ⁇ ) 2 , -COOR 2 , straight chained or branched C1-C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C 1 -C7 polyfluoroalkyl, straight chained or branched C 2 -C alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ; wherein each R 19 is independently H, or straight chained or branched C -C 6 alkyl;
- each R 2i is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C cycloalkyl, C 3 -C 7 cycloalkenyl, aryl or aryl(C ⁇ - C e ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- q is an integer from 2 to 4 inclusive;
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, -F, -Cl , -Br, -I , CN, methyl , ethyl , propyl , methoxy or ethoxy; wherein X is ; NR ⁇ R ⁇ 2 ;
- R u is H, straight chained or branched C 1 -C7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , aryl, or aryl (C ⁇ -C 3 ) alkyl;
- R 12 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R 13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C ⁇ 0 cycloalkyl, heteroaryl, aryl, aryl(C ⁇ - C 6 ) alkyl, & or Q 2 ;
- aryl may be substituted with one or more Ci-Cio straight chained or branched alkyl, aryl, heteroaryl, ⁇ or N(R ⁇ 9 )-Z;
- each J is independently O, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- R i4 is H, straight chained or branched C ! -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- R ⁇ 5 is straight chained or branched C 3 -C 3 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, (C(R 19 ) 2 ) m N(R ⁇ 6 ) 2 or
- R i6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i7 is independently H; -OR 2 ⁇ , -0C0R 2 ⁇ , -COR 2 ⁇ , -NCOR 21 , -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) , -COOR 2 ⁇ , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R ⁇ 8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 19 is independently H, or straight chained or branched Ci-Cg alkyl
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 21 , -OCOR 21/ -COR 21 , -NCOR 2 ⁇ , -N(R 2i ) 2 , - CON(R 2 ⁇ ) 2 , or -COOR2 1 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 21 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl (Ci- C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C ⁇ -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive; wherein each n is an integer from 1 to 4 inclusive;
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2 ;
- U is 0, -NR ⁇ 6 S, C(R 17 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C ⁇ -C-, cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy; wherein X is NRnR 2 ;
- Rn is H, straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , aryl or aryl (C ⁇ -C 6 ) alkyl;
- R 12 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or - ⁇ CH 2 ) m -Z;
- R X3 is a bicyclic alkyl ring system, aryl or aryl (C ⁇ -C 6 ) alkyl ;
- Y is NR 4 R 5 ;
- R i is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R i9 ) 2 ) m -Z;
- R 15 is straight chained or branched C 3 -C 3 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 3 cycloalkyl, or (C(R 19 ) 2 ) m -Z;
- U is O, -NR ⁇ 6 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- Rig is straight chained or branched C ⁇ -C alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ; wherein each R i7 is independently H; -OR 2 ⁇ , -OCOR21, -COR 2 ⁇ , -NCOR 21 , -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2/ -COOR 2 ⁇ , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C monofluor
- R 18 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) ra -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i9 is independently H, or straight chained or branched C ⁇ -C 3 alkyl
- each R 2 o is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 21 , -OCOR 2 ⁇ , -COR 21 , -NCOR 21 , -N(R 2 ⁇ ) 2 , - CON(R 2 ⁇ ) 2 , or -COOR21; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2i is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (Ci- C e ) alkyl;
- each m is an integer from 0 to 4 inclusive; wherein each n is an integer from 1 to 4 inclusive;
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure :
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R ⁇ 3 is an aryl, adamantyl, noradamantyl, C 3 -C ⁇ 0 cycloalkyl, heteroaryl, Q x or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R ⁇ 9 )-Z;
- each J is independently 0, S, C(R 22 ) 2 or NR 4 ; wherein R 4 is -H; straight chained or branched C ⁇ -C 7 alkyl, monof luoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl
- R ⁇ 5 is straight chained or branched C 3 -C e alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C e cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- U is 0, -NR ⁇ S , S, C(R 17 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl; wherein R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C 1 -C7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C-C alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R ⁇ 7 is independently H; -OR 2i , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR21, -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2 , -COOR21, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R 18 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i9 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 20 is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 21 , -OCOR 21 , -COR 2 ⁇ , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , - CON(R 2i ) 2 , or -COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2i is independently -H; straight chained or branched Q L -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (Ci- C 6 ) alkyl;
- each R 2 is independently H, F, Cl or C ⁇ -C 4 straight chained or branched alkyl ,-
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R ⁇ 3 is a bicyclic alkyl ring system, aryl or aryl (Ci-Cg) alkyl;
- Y is NR 14 R 15 ;
- R x4 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- R 15 is (C (R i9 ) 2 ) m -N(R ⁇ ) 2 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- R i6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, ( CH 2 ) m - Z , or (CH 2 ) q -0- ( CH 2 ) m - CH 3 ;
- each R 17 is independently H; -OR 2x , -OCOR 2 ⁇ , -C0R 2 ⁇ , -NCOR 21 , -N(R 2i ) 2 , -CON(R 2 ⁇ ) 2 , -COOR21, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- each R i9 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 2 ⁇ is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C ⁇ Cg) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- q is an integer from 2 to 4 inclusive;
- the invention provides a compound having the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R Xi is H, straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0- (CH 2 ) ra -CH 3 , aryl, or aryl (Ci-Cg) alkyl;
- R i is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R i3 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C ⁇ 0 cycloalkyl, heteroaryl, aryl, aryl(C ⁇ - Cg) alkyl, Q x or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C ⁇ 0 straight chained or branched alkyl, aryl, heteroaryl, or N(R 19 )-Z;
- each J is independently 0, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R 14 is H, straight chained or branched C ⁇ -C 5 alkyl, (CH 2 ) q -0- (CH 2 ) ra -CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) m -Z;
- R 15 is straight chained or branched C 3 -C 6 alkyl, (CH 2 )q-0-(CH 2 ) m -CH 3 , C 3 -C 3 cycloalkyl, (C (R X9 ) 2 ) m N(R 16 ) 2 or
- R i6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monof luoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 17 is independently H; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR21, -N(R 2X ) 2 , -CON(R 2 ⁇ ) 2 , -COOR21, straight chained or branched C 1 -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R ⁇ 8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i9 is independently H, or straight chained or branched C ⁇ -C 3 alkyl
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; -0R 2 ⁇ , -OCOR 2 ⁇ , -COR 21 , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , - CON(R 21 ) 2 , or -COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2i is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl (C x - C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C ⁇ -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive; wherein each n is an integer from 1 to 4 inclusive;
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2 ;
- U is 0, -NR 16 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 7 cyclic ether, C-C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a compound having the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- Rn is H, straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , aryl or aryl (C ⁇ -C 6 ) alkyl;
- R ⁇ 2 is straight chained or branched C-C 7 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R ⁇ 3 is a bicyclic alkyl ring system, aryl or aryl (C ⁇ -C 6 ) alkyl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R ⁇ 4 is H, straight chained or branched C ⁇ -C 6 alkyl , (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl , or (C (R i9 ) 2 ) m -Z ;
- R ⁇ 5 is straight chained or branched C 3 -C 3 alkyl , (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R i9 ) 2 ) m -Z;
- U is O, -NR ⁇ 6/ S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ S ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- Ri is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 17 is independently H; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , -C0N(R 2 ⁇ ) 2 , -COOR 2i , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R 18 is straight chained or branched Cx-C alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 19 is independently H, or straight chained or branched C ⁇ -C 5 alkyl
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 21 , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR 2i , -N(R 21 ) 2 , - CON(R 2 ⁇ ) 2 , or -COOR 21 ; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group,-
- each R 2 ⁇ is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (O . - C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the invention provides a compound having the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R 13 is an aryl, adamantyl, noradamantyl, C 3 -C ⁇ 0 cycloalkyl, heteroaryl, Q x or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C ⁇ 0 straight chained or branched alkyl, aryl, heteroaryl, or N(R ⁇ 9 )-Z;
- each J is independently 0, S, C(R 22 ) 2 or NR 4 ;
- R 4 is -H; straight chained or branched C 1 -C 7 alkyl , monof luoroalkyl or polyfluoroalkyl ; straight chained or branched C 2 -C alkenyl or alkynyl ; C 3 -C 7 cycloalkyl , C 5 -C 7 cycloalkenyl or aryl ;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R 14 is H, straight chained or branched C ⁇ -C 3 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -Cg cycloalkyl, or (C (R i9 ) 2 ) m -Z;
- R ⁇ 5 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R i9 ) 2 ) m -Z;
- U is O, -NR X6 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- R ⁇ 6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl , straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i7 is independently H; -OR 2 ⁇ , -OCOR 2i , -COR 2 ⁇ , -NCOR21, -N(R 21 ) 2 , -CON(R 2 ⁇ ) 2 , -COOR21, straight chained or branched C 1 -C7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -Or (CH 2 ) m -CH 3 ;
- R ⁇ 8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) ra -CH 3 ;
- each R i9 is independently H, or straight chained or branched C ⁇ -C 6 alkyl; wherein each R 20 is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; -OR 2 ⁇ , -OCOR 21 , -COR 2 ⁇ , -NCOR 2 ⁇ , -N(R 2i ) 2 , - CON(R 2i ) , or -COOR21; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group
- each R 21 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl(C ⁇ - C 6 ) alkyl;
- each R 22 is independently H, F, Cl or C ⁇ -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive,-
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the invention provides a compound having the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R i3 is a bicyclic alkyl ring system, aryl or aryl (C ⁇ -C 6 ) alkyl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -Cg cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- R i5 is (C (R 19 ) 2 ) ra -N (R ⁇ 6 ) 2,
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl; wherein R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 )q-0-(CH 2 ) m -CH 3 ;
- each R 17 is independently H; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR 2 i, -N(R 2 ⁇ ) 2 -CON(R 2 ⁇ ) 2 , -COOR 2 ⁇ , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- each R ⁇ 9 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 21 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C x - C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- q is an integer from 2 to 4 inclusive;
- the invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure.
- each of Y l r Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched C-C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NC0R 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR ; aryl or heteroaryl; or any two of Y ⁇ , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C ⁇ -C ⁇ ) alkyl; wherein A is A' , Q 3 , Q 4 , Q 5 , straight chained or branched C ⁇ -C 7 alkyl, aryl, heteroaryl, aryl (C x - C e ) alkyl, heteroaryl (C ⁇ -C 3 ) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR ⁇ 7 ) - (CHR ⁇ 7 ) n -Z;
- Ri and R 2 are each independently H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, - N0 2 , or -CN;
- R 3 is H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, -N0 2 , -CN, -OR 6 , aryl or heteroaryl;
- R s is straight chained or branched C ⁇ -C 7 alkyl, -N(R 4 ) 2 , ⁇ OR 6 or aryl; wherein R 6 is straight chained or branched C x -C 7 alkyl or aryl ,-
- each R i7 is independently H; straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0-
- each R 20 is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; - OR 2 ⁇ , -OCOR 2l7 -COR 2 ⁇ , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2 , or -COOR 21 ; aryl or heteroaryl; or two R 2 o groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2i is independently -H; straight chained or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl; wherein each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, -NR ⁇ 6 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl , C 4 -C 7 cyclic ether, C 4 -C 7 cyclic thioether, aryl , or heteroaryl ;
- R ⁇ 6 is straight chained or branched C ⁇ -C 7 alkyl , straight chained or branched C ⁇ -C 7 monof luoroalkyl , straight chained or branched C ⁇ -C 7 polyfluoroalkyl , straight chained or branched C 2 -C 7 alkenyl , straight chained or branched C -C 7 alkynyl , C 5 -C7 cycloalkenyl , - (CH 2 ) m -Z , or (CH 2 ) q -0- (CH 2 ) m -CH 3 ;
- q is an integer from 2 to 4 inclusive ;
- B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy; wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- each R 22 is independently H, F,
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure :
- each of Y lf Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C cycloalkyl, or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -0C0R 4 , -COR 4 , -NCOR 4 , - N(R 4 ) 2 , -C0N(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y 1; Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is A' , straight chained or branched C ⁇ -C 7 alkyl, aryl, heteroaryl, aryl (C ⁇ -C 6 ) alkyl or heteroaryl (C ⁇ -C 6 ) alkyl ;
- Ri and R 2 are each independently H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, - N0 2 , or -CN;
- R 3 is H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, -N0 2 , -CN, -OR 6 aryl or heteroaryl;
- R 5 is straight chained or branched C ⁇ -C 7 alkyl, -N(R 4 ) 2 , -OR 6 or aryl;
- R 6 is straight chained or branched C ⁇ -C 7 alkyl or aryl ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- n is an integer from 1 to 4 inclusive;
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- each of Y l t Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched C ⁇ -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y 1# Y , Y 3 and Y 4 present on adjacent carbon atoms can constitute a methyl
- each R 4 is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C G ) alkyl;
- A is A' , straight chained or branched C ⁇ -C 6 alkyl, aryl, heteroaryl, aryl (C-C 6 ) alkyl or heteroaryl (C ⁇ -C 6 ) alkyl; wherein A' is
- B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q s ;
- a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- n is an integer from 1 to 4 inclusive; wherein each R 22 is independently H, F, Cl, or straight chained or branched C ⁇ -C 4 alkyl;
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure :
- each of Y 1# Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y ⁇ 7 Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a methylened
- A is Q 3 , Q , Q 5 , aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR 17 ) - (CHR 17 ) n -Z;
- each R ⁇ 7 is independently H; straight chained or branched C ⁇ -C? alkyl, straight chained or branched
- C ⁇ -C 6 monofluoroalkyl straight chained or branched Cx-C 6 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- each R 20 is independently -H; straight chained or branched C ⁇ -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 6 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; - OR 2 ⁇ , -OCOR 2 ⁇ , -C0R 2 ⁇ , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , -C0N(R 2 ⁇ ) 2 , or -COOR 2 ⁇ ; aryl or heteroaryl; or two R 2 o groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2 ⁇ is independently -H; straight chained or branched C ⁇ -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl; wherein each R 22 is independently H, F, Cl, or straight chained or branched C ⁇ -C 4 alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, -NR ⁇ 6 , S, C(R 17 ) 2 , or -NS0 2 R ⁇ e ;
- Z is C 3 -C 10 cycloalkyl, C 4 -C 6 cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 6 monofluoroalkyl, straight chained or branched C ⁇ -C 6 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C? cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) q -0- (CH 2 ) m -CH 3 ;
- q is an integer from 2 to 4 inclusive
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- each of Y X/ Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched C ⁇ -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y l t Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 3 ) alkyl;
- A is A' , Q 3 , Q 4/ Q 5 , straight chained or branched C ⁇ -C 6 alkyl, aryl, heteroaryl, aryl (C ⁇ C 6 ) alkyl, heteroaryl (C ⁇ -C 6 ) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHRi ? ) - (CHRi ? ) n -Z;
- R x and R 2 are each independently H, straight chained or branched Ci-C 6 alkyl, -F, -Cl, -Br, -I, - N0 2 , or -CN;
- R 3 is H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, -N0 2 , -CN, -OR 6 , aryl or ⁇ heteroaryl;
- R 5 is straight chained or branched C ⁇ -C 7 alkyl, -N(R 4 ) 2 , -OR 6 or aryl; wherein R ⁇ is straight chained or branched Ci-C 6 alkyl or aryl ;
- each R ⁇ 7 is independently H; straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched
- C ⁇ -C 7 monofluoroalkyl straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 3 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- each R 0 is independently -H; straight chained or branched C -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl or C 3 -C 6 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; - OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR 21 , -N(R 2i ) 2 , -CON(R 21 ) 2 , or -COOR 2 i; aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2 ⁇ is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl ;
- each m is an integer from 0 to 4 inclusive; wherein each n is an integer from 1 to 4 inclusive;
- each p is an integer from 0 to 2 inclusive;
- U is O, -NR 16 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ e ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 6 cyclic ether, C 4 -C 6 cyclic thioether, aryl, or heteroaryl;
- R ⁇ 6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) q -0- (CH 2 ) m -CH 3 ;
- q is an integer from 2 to 4 inclusive
- B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy; wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- each R 22 is independently H, F,
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- each of Y 1# Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C-C 6 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR, -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -C00R 4 ; aryl or heteroaryl; or any two of Yi, Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a methylenedioxy group;
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is A' , straight chained or branched Ci-C 6 alkyl, aryl, heteroaryl, aryl (C ⁇ -C 3 ) alkyl or heteroaryl (C ⁇ -C 3 ) alkyl ;
- R x and R 2 are each independently H, straight chained or branched Ci-C 6 alkyl, -F, -Cl, -Br, -I, - N0 2 , or -CN;
- R 3 is H, straight chained or branched Ci-C 6 alkyl, -F, -Cl, -Br, -I, -N0 2 , -CN, -OR 6 aryl or heteroaryl;
- R 5 is straight chained or branched Ci-C 6 alkyl, -N(R 4 ) 2 , -OR 5 or aryl;
- R s is straight chained or branched Q L -C 6 alkyl or aryl ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- n is an integer from 1 to 4 inclusive;
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- each of Y 1# Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, or C 5 -C 6 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -C00R 4 ; aryl or heteroaryl; or any two of Yi, Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a methylenedi
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is A' , straight chained or branched Ci-C 6 alkyl, aryl, heteroaryl, aryl (C ⁇ -C 3 ) alkyl or heteroaryl (C ⁇ -C 3 ) alkyl; wherein A' is
- B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q s ;
- a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- n is an integer from 1 to 4 inclusive;
- each R 22 is independently H, F, Cl, or straight chained or branched C ⁇ -C 4 alkyl
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- each of Y l r Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR ⁇ - N(R 4 ) 2 , -C0N(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y x , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute
- each R is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C? cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is Q 3 , Q 4 , Q 5 , aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHRi?) - (CHRi?) n -Z;
- each R i7 is independently H; straight chained or branched C ⁇ -C 6 alkyl, straight chained or branched C ⁇ -C 6 monofluoroalkyl , straight chained or branched C ⁇ -C 6 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C? alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0-
- each R 2 o is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl or C 5 -C 6 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; - 0R 2 ⁇ , -0C0R 2 ⁇ , -COR 21 , -NCOR 21 , -N(R 21 ) 2 , -C0N(R 2 ⁇ ) 2 , or -CO0R 2 ⁇ ,- aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2 ⁇ is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl or aryl;
- each R 22 is independently H, F, Cl, or straight chained or branched C ⁇ -C alkyl
- q is an integer from 2 to 4 inclusive
- each m is an integer from 0 to 4 inclusive;
- each n is an integer from 1 to 4 inclusive; wherein each p is an integer from 0 to 2 inclusive;
- U is 0, -NR 16 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ S ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 7 cyclic ether,
- R ⁇ S is straight chained or branched C ⁇ -C 6 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) q -0- (CH 2 ) m -CH 3 ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure :
- each of Y 1# Y, Y 3 , and Y 4 is independently - H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 3 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -0R 4 , -SR 4 , -0C0R 4 , -C0R , -NC0R 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -C00R 4/ - aryl or heteroaryl; or any two of Yi, Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C? cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is A' , Q 3 , Q 4 , Q 5 , straight chained or branched C ⁇ -C? alkyl, aryl, heteroaryl, aryl (Ci- C 6 ) alkyl, heteroaryl (C ⁇ -C 6 ) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHRi ? ) - (CHRi ? ) n -Z; wherein A' is
- Rx and R 2 are each independently H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, - N0 2 , or -CN;
- R 3 is H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, -N0 2 , -CN, -OR 6 , aryl or heteroaryl ;
- R 5 is straight chained or branched C ⁇ -C 7 alkyl, -N(R 4 ) 2 , -OR s or aryl; wherein R 6 is straight chained or branched C ⁇ -C 7 alkyl or aryl ;
- each R i7 is independently H; straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched Ci-C 6 monofluoroalkyl, straight chained or branched Ci-C 6 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0-
- each R 2 o is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C? alkenyl or alkynyl; C 3 -C 6 cycloalkyl or C 5 -C 6 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; - OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NC0R 2 ⁇ , -N(R 2i ) 2 , -CON(R 21 ) 2 , or -COOR 2 ⁇ ,- aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R i is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C x -C 6 ) alkyl; wherein each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive,-
- each p is an integer from 0 to 2 inclusive,-
- U is O, -NR 16 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R 16 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 6 cyclic ether, C 4 -C 6 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) q -0- (CH 2 ) m -CH 3 ;
- q is an integer from 2 to 4 inclusive
- B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q s ; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy; wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- each R 22 is independently H, F,
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure :
- each of Y ⁇ ; Y, Y 3 , and Y 4 is independently H; straight chained or branched Q L -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, or C 5 -C?
- cycloalkenyl -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -C0R 4 , -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Yi, Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a methylenedioxy group;
- each R 4 is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C;j . -C 6 ) alkyl;
- A is A' , straight chained or branched Q L -C 6 alkyl, aryl, heteroaryl, aryl (C ⁇ -C 6 ) alkyl or heteroaryl (C ⁇ -C e ) alkyl;
- Rx and R 2 are each independently H, straight chained or branched Ci-C 6 alkyl, -F, -Cl, -Br, -I, -
- R 3 is H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, -N0 2 , -CN, -OR 6 aryl or heteroaryl;
- R 5 is straight chained or branched Ci-C 6 alkyl, -N(R 4 ) 2 , -OR 6 or aryl;
- R 6 is straight chained or branched Ci-C 6 alkyl or aryl ,-
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- n is an integer from 1 to 4 inclusive;
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:
- each of Y l r Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched Q L -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, or C 3 -C 6 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y 1# Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C? cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is A' , straight chained or branched Ci-C 6 alkyl, aryl, heteroaryl, aryl (C ⁇ -C 6 ) alkyl or heteroaryl (C ⁇ -C 6 ) alkyl;
- B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ;
- a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;
- n is an integer from 1 to 4 inclusive;
- each R 22 is independently H, F, Cl, or straight chained or branched C ⁇ -C 4 alkyl
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure :
- each of Yi, Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y x , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a methylenedi
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is Q 3 , Q 4 , Q 5 , aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHRi ? ) - (CHR 17 ) n -Z;
- each R x7 is independently H; straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched
- Ci-C 6 monofluoroalkyl straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C-C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; - OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NC0R 21 , -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2 , or -COOR 2 ⁇ ,- aryl or heteroaryl; or two R 20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2 is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 6 cycloalkenyl or aryl; wherein each R 22 is independently H, F, Cl, or straight chained or branched C ⁇ -C 4 alkyl;
- q is an integer from 2 to 4 inclusive
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is O, -NR i6 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ ⁇ ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 6 cyclic ether, C 4 -C 6 cyclic thioether, aryl, or heteroaryl;
- R ⁇ 6 is straight chained or branched Ci-C 6 alkyl, straight chained or branched Cx-C 6 monofluoroalkyl, straight chained or branched C -C 6 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 6 alkynyl, Cs-C 6 cycloalkenyl, -(CH 2 ) ra -Z, or (CH 2 ) q -0- (CH 2 ) m -CH 3 ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- each of Y x , Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -0R 4 , -SR 4 , -0C0R 4 , -C0R 4 , -NC0R 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -C00R 4 ; aryl or heteroaryl; or any two of Y ⁇ # Y 2 , Y 3 and Y 4 present on adjacent carbon atoms
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is A', Q 3 , Q 4 , Q 5 straight chained or branched C ⁇ -C 7 alkyl, aryl, heteroaryl, aryl (C ⁇ C ⁇ ) alkyl, heteroaryl (C ⁇ -C 6 ) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHRi ? ) - (CHRi ? ) n -Z;
- R x and R 2 are each independently H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, - N0 2 , or -CN;
- R 3 is H, straight chained or branched Ci-C 6 alkyl, -F, -Cl, -Br, -I, -N0 2 , -CN, -OR 6 , aryl or heteroaryl; wherein R 5 is straight chained or branched Ci-C 6 alkyl, -N(R) 2 , -OR 6 or aryl;
- R 6 is straight chained or branched C ⁇ C 7 alkyl or aryl ;
- each R i7 is independently H; straight chained or branched Ci-C 6 alkyl, straight chained or branched Ci-C 6 monofluoroalkyl, straight chained or branched
- Ci-C 6 polyfluoroalkyl straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C? cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- each R 20 is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or C 5 -C 6 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; -
- each R i is independently -H; straight chained or branched Q L -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C ⁇ ) alkyl; wherein each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is 0, -NR ⁇ 6 , S, C(R 17 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 6 cyclic ether,
- R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) q -0- (CH 2 ) m -CH 3 ;
- q is an integer from 2 to 4 inclusive
- B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine,-
- each R 2 is independently H, F,
- the invention provides a compound having the structure:
- each of Yi, Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, or C 5 -C 6 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -0R 4 , -SR 4 , -0C0R 4 , -C0R 4 , -NC0R 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Yi, Y / Y 3 and Y present on adjacent carbon atoms can constitute a methylenedioxy
- each R 4 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is A' , straight chained or branched C ⁇ -C 7 alkyl, aryl, heteroaryl, aryl (C ⁇ -C 6 ) alkyl or heteroaryl (C ⁇ -C 3 ) alkyl;
- R x and R 2 are each independently H, straight chained or branched C ⁇ -C 7 alkyl, -F, -Cl, -Br, -I, - N0 2 , or -CN;
- R 3 is H, straight chained or branched C-C 6 alkyl, -F, -Cl, -Br, -I, -N0 2 , -CN, -OR s aryl or heteroaryl;
- R 5 is straight chained or branched Ci-C 6 alkyl, -N(R 4 ) 2 , -OR s or aryl;
- R s is straight chained or branched Ci-C 6 alkyl or aryl ,-
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- n is an integer from 1 to 4 inclusive;
- the invention provides a compound having the structure:
- each of Y , Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, or C 5 -C 6 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -0R 4 , -SR 4 , -OCOR 4 , -C0R 4 , -NC0R 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a
- each R 4 is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is A' , straight chained or branched C ⁇ -C 7 alkyl, aryl, heteroaryl, aryl (C ⁇ -C 6 ) alkyl or heteroaryl (C ⁇ -C 6 ) alkyl;
- B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q 6 ;
- a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine,-
- n is an integer from 1 to 4 inclusive; wherein each R 22 is independently H, F, Cl, or straight chained or branched C ⁇ -C 4 alkyl;
- the invention provides a compound having the structure:
- each of Y x , Y 2 , Y 3 , and Y 4 is independently - H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C?
- alkenyl or alkynyl C 3 -C 7 cycloalkyl, or C 5 -C 6 cycloalkenyl; -F, -Cl, -Br, or - I; -N0 2 ; -N 3 ; -CN; -0R 4 , -SR 4 , -0C0R 4 , -COR 4 , -NCOR 4 , - N(R 4 ) 2 , -CON(R 4 ) 2 , or -COOR 4 ; aryl or heteroaryl; or any two of Y x , Y 2 , Y 3 and Y 4 present on adjacent carbon atoms can constitute a methylenedioxy group;
- each R 4 is independently -H; straight chained or branched Ci-C? alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (C ⁇ -C 6 ) alkyl;
- A is Q 3 , Q 4 , Q s , aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHRi ? ) - (CHRi ? ) n -Z ;
- each R 1 is independently H; straight chained or branched Ci-C 6 alkyl, straight chained or branched
- each R 20 is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br, or -I; -N0 2 ; -N 3 ; -CN; - 0R 2 ⁇ , -OCOR21, -C0R 2 ⁇ , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2 , or -C00R 2 ⁇ ; aryl or heteroaryl; or two R 2 o groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
- each R 2 ⁇ is independently -H; straight chained or branched Ci-C? alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl or aryl; wherein each R 22 is independently H, F, Cl, or straight chained or branched C ⁇ -C 4 alkyl;
- q is an integer from 2 to 4 inclusive
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- each p is an integer from 0 to 2 inclusive;
- U is 0, -NR ⁇ 6 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 6 cyclic ether, C 4 -C 6 cyclic thioether, aryl, or heteroaryl;
- R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) q -0- (CH 2 ) m -CH 3 ;
- B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;
- the invention provides a method of treating depression in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist, wherein:
- the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human GALl receptor;
- the GAL3 receptor antagonist does not inhibit the activity of central monoamine oxidase A greater than 50 percent, at a concentration of 10 ⁇ M;
- the GAL3 receptor antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 percent, at a concentration of lO ⁇ M;
- the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least tenfold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.
- the invention provides a method of treating anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist, wherein:
- the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human GALl receptor; and (b) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters : serotonin transporter, norepinephrine transporter, and dopamine transporter.
- rats were examined in a 5 minute forced swim test. For each treatment condition, the number of 5-sec intervals culminating with a display of climbing was derived and plotted as the average +/- S.E.M.
- Example 92 A significant increase in climbing was observed for rats injected with Example 92 at 10 mg/kg, relative to vehicle injected controls (p ⁇ 0.01, ANOVA and Student-Nerman-Keuls) , but not in rats dosed with Example 92 at 30 mg/kg ip .
- rats were examined in a 5 minute forced swim test.
- the number of 5-sec intervals culminating with a display of swimming was derived and plotted as the average +/- S.E.M.
- a significant increase in swimming was observed for rats injected with fluoxetine at 10 mg/kg ip or with Example 92 at 30 mg/kg, relative to vehicle injected controls (p ⁇ 0.01, ANOVA and Student-Nerman-Keuls).
- n 5 for each treatment condition
- unfamiliar rats were examined in a 15 minute social interaction test.
- the amount of time spent in social interaction was derived and plotted as the average +/- S.E.M.
- a significant increase in social interaction was observed for rats injected with chlordiazepoxide at 5 mg/kg i.p. or with Example 92 at 10 mg/kg ip (p ⁇ 0.05) as well as 30 mg/kg (p ⁇ 0.01) .
- Example 92 When the dose of Example 92 was increased to 100 mg/kg, the amount of social interaction time was significantly less than measured after chlordiazepoxide at 5 mg/kg ip or Example 92 at 30 mg/kg ip (p ⁇ 0.01) . Significance in all cases was determined by ANOVA and Student-Nerman-Keuls.
- the anti- GAL3 antiserum labeled proteins in membranes only from rat GAL3-transfected cells (Lane 2) ; a predominant band was evident with an apparent molecular weight of approximately 56 kDa, (somewhat higher than the amino acid-derived value of ⁇ 40.4 kDa) .
- the apparently high molecular weight observed for rat GAL3 very likely reflects post-translational processing such as glycosylation; note that rat GAL3 contains multiple N- terminal glycosylation sites (Smith et al . , 1998).
- Relative to the predominant band additional species of higher molecular weight as well as lower molecular weight were labeled by the GAL3 antiserum. These are interpreted as protein aggregates of C-terminal fragments, as they are absent in mock-transfected cells.
- the present invention • provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- X is; NR ⁇ R 12 ;
- R xx is H, straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , aryl, or aryl (C ⁇ -C 6 ) alkyl;
- R X is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R i3 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C ⁇ 0 cycloalkyl, heteroaryl, aryl, aryl(C ⁇ - C s ) alkyl, Q x or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C 10 straight chained or branched alkyl, aryl, heteroaryl, or N(R ⁇ 9 ) -Z;
- each J is independently O, S, C(R 2 ) 2 or NR 4 ; wherein R 4 is H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 7 cycloalkenyl or aryl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R ⁇ 4 is H, straight chained or branched C ⁇ -C e alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R i9 ) 2 ) m -Z;
- R i5 is straight chained or branched C 3 -C 3 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C ⁇ cycloalkyl, (C (R i9 ) 2 ) m N (R 16 ) 2 or (C (R ⁇ 9 ) 2 ) m ⁇ Z ;
- R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C? alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 6 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 )q-0-(CH 2 ) m -CH 3 ;
- each R 17 is independently H; -0R 2 ⁇ , -OCOR 2 ⁇ , -C0R 21 , -NCOR 2i , -N(R 21 ) 2 , -CON(R 21 ) 2 , -COOR 21 , straight chained or branched C-C 7 alkyl, straight chained or branched C-C 6 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R i8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R X9 is independently H, or straight chained or branched C ⁇ -C 3 alkyl
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 - C ?
- each R 2 ⁇ is independently -H; straight chained or branched C ⁇ -C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl, or aryl (d- C 6 ) alkyl;
- each R 2 is independently H, F, Cl or C ⁇ -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- U is O, -NR ⁇ 6 , S, C(R ⁇ ?) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C? cyclic ether, C 4 -C 7 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure :
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R x is H, straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , aryl or aryl (C ⁇ -C 6 ) alkyl;
- R 2 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) g -0-(CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R 13 is a bicyclic alkyl ring system, aryl or aryl (C ⁇ -C 6 ) alkyl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 3 cycloalkyl, or (C (R i9 ) 2 ) m -Z;
- R 1 5 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- U is 0, -NR ⁇ S , S, C(R ⁇ 7 ) 2 , or -NS0 2 R 1S ;
- Z is C 3 -C 10 cycloalkyl, aryl, or heteroaryl
- R 16 is straight chained or branched C ⁇ -C 6 alkyl, straight chained or branched C-C 7 monofluoroalkyl, straight chained or branched C ⁇ -C? polyfluoroalkyl, straight chained or branched C 2 -C?
- each R ⁇ 7 is independently H; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 21 , -NCOR21, -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2 , -COOR 21 , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C -C monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 7 cycloalkenyl,
- R X8 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 19 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 2 o is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 - C?
- each R 2 ⁇ is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C? cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl(C ⁇ - C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive; wherein p is an integer from 0 to 2 inclusive;
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure :
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R i3 is an aryl, adamantyl, noradamantyl, C 3 -C ⁇ 0 cycloalkyl, heteroaryl, Qi or Q 2 ;
- aryl may be substituted with one or more C-Cio straight chained or branched alkyl, aryl, heteroaryl, or N(R i9 ) -Z;
- each J is independently 0, S, C(R 22 ) 2 or NR 4 ; wherein R 4 is -H; straight chained or branched C ⁇ -C 7 alkyl, monof luoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl or aryl;
- Y is NR ⁇ 4 R ⁇ 5 ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 3 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- R ⁇ 5 is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 3 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- U is 0, -NR ⁇ S , S, C(R 17 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl; wherein R ls is straight chained or branched C ⁇ -C 6 alkyl, straight chained or branched Ci-C 6 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R ⁇ 7 is independently H; -0R 2 ⁇ , -OCOR 21 , -COR 2 ⁇ , -NC0R 2 ⁇ , -N(R 2 ⁇ ) 2 / -C0N(R 2 ⁇ ) 2 , -C00R 2 ⁇ , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C x -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R 18 is straight chained or branched C ⁇ -C 3 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R i9 is independently H, or straight chained or branched C x -C 6 alkyl
- each R 20 is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 - C ?
- each R 21 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -
- each R 22 is independently H, F, Cl or C ⁇ -C 4 straight chained or branched alkyl
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2 ;
- the invention provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R ⁇ 3 is a bicyclic alkyl ring system, aryl or aryl (C ⁇ -C 3 ) alkyl;
- Y is NR 14 R ⁇ 5 ;
- R 14 is H, straight chained or branched Ci-C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 3 cycloalkyl, or (C (R 19 ) 2 ) m -Z;
- R 15 is (C (R 19 ) 2 ) m -N(R ⁇ 6 ) 2 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- R i6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C? polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 6 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) ra -CH 3 ;
- each R 17 is independently H; -OR 2 ⁇ , -0C0R 2i , -C0R 2 ⁇ , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , -C0N(R 2 ⁇ ) 2 , -COOR2 1 , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 6 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- each R ⁇ 9 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 2 ⁇ is independently -H; straight chained or branched Ci-C 6 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 - C ? cycloalkyl, C 5 -C 7 cycloalkenyl, aryl or aryl (C x - C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- q is an integer from 2 to 4 inclusive;
- bicyclic alkyl ring systems includes, but is not limited to, bicyclo [2.2.1] heptane, bicyclo [3.1.1] heptane and bicyclo [2.2.2] octane.
- the bicyclic alkyl ring systems may be substituted with one or more of the following: -F, -N0 2 , -CN, straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 5 -C 7 cycloalkenyl, -N(R 21 ) 2 , -0R 2 ⁇ , -C0R 2i , - C0 2 R 2 ⁇ , -C0N (R 2 ⁇ ) 2 or ( CH 2 ) n -0- ( CH 2 ) m - CH 3 .
- cycloalkyl includes, C 3 -C 6 cycloalkyl moieties which may be substituted with one or more of the following: -F, -N0 2 , -CN, straight chained or branched Ci-C 6 alkyl, straight chained or branched Ci-C 6 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C?
- alkynyl C 3 -C 6 cycloalkyl, C 3 -C 6 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 6 cycloalkenyl, -N(R 4 ) 2 , -0R 4 , -C0R 4 , -NC0R 4 , -C0 2 R 4 , C0N(R 4 ) 2 or (CH 2 ) n -0- (CH 2 ) m -CH 3 .
- cyclohexyl includes, cyclohexyl groups which may be substituted with one or more of the following: -F, -N0 2 , -CN, straight chained or branched Ci-C? alkyl, straight chained or branched Ci-C?
- cycloalkenyl includes, C 5 -C 6 cycloalkenyl moieties which may be substituted with one or more of the following: -F, -Cl, -Br, -I, -N0 2 , -CN, straight chained or branched Ci-C 6 alkyl, straight chained or branched Ci-C?
- Ci-C 6 polyfluoroalkyl straight chained or branched Ci-C 6 polyfluoroalkyl, straight chained or branched C 2 -C 6 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 6 monofluorocycloalkyl, C 3 -C 7 polyfluorocycloalkyl, C 5 -C 6 cycloalkenyl, -N(R 4 ) 2 , -0R 4 , -C0R 4 , -NCOR 4 , -C0 2 R 4 , C0N(R 4 ) 2 or (CH 2 ) n -0-(CH 2 ) m -CH3.
- heteroaryl is used to include five and six membered unsaturated rings that may contain one or more oxygen, sulfur, or nitrogen atoms.
- heteroaryl groups include, but are not limited to, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl .
- heteroaryl is used to include fused bicyclic ring systems that may contain one or more heteroatoms such as oxygen, sulfur and nitrogen.
- heteroaryl groups include, but are not limited to, indolizinyl, indolyl, isoindolyl, benzo [b] furanyl, benzo [b] thiophenyl, indazolyl, benzimidazolyl, purinyl, benzoxazolyl, benzisoxazolyl, benzo [b] thiazolyl, imidazo [2 , 1-b] thiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1, 8-naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, phthalimidyl and 2, 1, 3-benzothiazolyl .
- heteroaryl also includes those chemical moieties recited above which may be substituted with one or more of the following: -F, -Cl, -Br, -I, -N0 2 , -CN, straight chained or branched Ci-C 6 alkyl, straight chained or branched Ci-C?
- heteroaryl further includes the N-oxides of those chemical moieties recited above which include at least one nitrogen atom.
- aryl is phenyl or naphthyl .
- the term “aryl” also includes phenyl and naphthyl which may be substituted with one or more of the following: -F, -Cl, -Br, -I, -N0 2 , -CN, straight chained or branched Ci-C 6 alkyl, straight chained or branched Ci-C 6 monofluoroalkyl, straight chained or branched Ci-C 6 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 3 -C 7 monofluorocycloalkyl, C 3 -C 6 polyfluorocycloalkyl, C 5 -C?
- the compound is enantiomerically and diasteriomerically pure. In one embodiment, the compound is enantiomerically or diasteriomerically pure.
- the compound in one embodiment of any of the methods described herein, can be administered orally.
- X is:
- X is NRnR ⁇ 2 and R n is H or straight chained or branched C ⁇ -C 7 alkyl.
- the compound has the structure
- R ⁇ 3 is a bicyclic alkyl ring system, cyclohexyl or aryl .
- R 14 is H, straight chained or branched Ci-Cs alkyl or (CH 2 ) q -0- (CH 2 ) m -CH 3 .
- R ⁇ 4 is H, straight chained or branched C ⁇ -C 6 alkyl or (CH 2 ) q -0- (CH 2 ) m -CH 3 .
- the compound is selected from the group consisting of:
- Y is
- U is NR ⁇ 6 .
- R 16 is (CH 2 ) m -Z.
- Z is aryl or heteroaryl.
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- Y is
- U is NR 16 .
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the compound is selected from the group consisting of:
- the compound is selected from the group consisting of:
- X is N(CH 3 ) 2 .
- Y is
- R 13 is an aryl substituted with a C ⁇ -C 10 straight chained alkyl .
- the compound is selected from a group consisting of :
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- X is; NRnR ⁇ 2 ;
- Rn is H, straight chained or branched Q L -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , aryl, or aryl (C ⁇ -C 6 ) alkyl; wherein R x2 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R i3 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C 3 -C ⁇ 0 cycloalkyl, heteroaryl, aryl, aryl (Ci- C 6 ) alkyl, Q x or Q 2 ;
- aryl may be substituted with one or more C ⁇ -C ⁇ 0 straight chained or branched alkyl, aryl, heteroaryl, or N(R ⁇ 9 )-Z;
- each J is independently 0, S, C(R 22 ) 2 or NR 4 ;
- R 4 is H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 6 alkenyl or alkynyl; C 3 -C 6 cycloalkyl, C 5 -C 6 cycloalkenyl or aryl;
- R ⁇ 4 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C(R 19 ) 2 ) n -Z;
- R 1S is straight chained or branched C 3 -C 5 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, (C (R 19 ) 2 ) m N (R 16 ) 2 or (C (Rig) 2 ) m ⁇ Z ;
- R 16 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 7 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 17 is independently H; -0R 21 , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR21, -N(R 2 ⁇ ) 2 , -C0N(R 2 ⁇ ) 2 , -COOR21, straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl , straight chained or branched C ⁇ -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 7 alkynyl, C 5 -C 7 cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R 18 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) ra -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R 19 is independently H, or straight chained or branched C ⁇ -C 6 alkyl
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C 7 alkenyl or alkynyl; C 3 - C ?
- each R 2 ⁇ is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C? alkenyl or alkynyl; C 3 - C ? cycloalkyl, C 5 -C 7 cycloalkenyl, aryl, or aryl (C ⁇ C 6 ) alkyl; wherein each R 2 is independently H, F, Cl or C ⁇ -C 4 straight chained or branched alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive
- p is an integer from 0 to 2 inclusive
- q is an integer from 2 to 4 inclusive
- t is 1 or 2;
- U is O, -NR ⁇ 6 , S, C(R ⁇ ? ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, C 4 -C 7 cyclic ether, C 4 -C 6 cyclic thioether, aryl, or heteroaryl; or
- the invention provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:
- W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
- R u is H, straight chained or branched Ci-C 6 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , aryl or aryl (C-.-C 6 ) alkyl;
- R i2 is straight chained or branched C ⁇ -C 7 alkyl, (CH 2 ) q -0- (CH 2 ) m -CH 3 , or -(CH 2 ) m -Z;
- R i3 is a bicyclic alkyl ring system, aryl or aryl (C ⁇ -C 6 ) alkyl;
- Y is NR 1 R 15 ;
- R i4 is H, straight chained or branched C ⁇ -C 6 alkyl, (CH 2 ) q -0-(CH 2 ) ra -CH 3 , C 3 -C 6 cycloalkyl, or (C(R X$ ) 2 ) m -Z;
- R ⁇ S is straight chained or branched C 3 -C 6 alkyl, (CH 2 ) q -0-(CH 2 ) m -CH 3 , C 3 -C 6 cycloalkyl, or (C(R ⁇ 9 ) 2 ) m -Z;
- U is O, -NR X6 , S, C(R ⁇ 7 ) 2 , or -NS0 2 R ⁇ 6 ;
- Z is C 3 -C ⁇ 0 cycloalkyl, aryl, or heteroaryl
- R ⁇ 6 is straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C ⁇ -C 7 monofluoroalkyl, straight chained or branched Q L -C 6 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C 2 -C 6 alkynyl, C 5 -C 6 cycloalkenyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ; wherein each R ⁇ 7 is independently H; -OR 2 ⁇ , -OCOR 2 ⁇ , -COR 2 ⁇ , -NCOR 2 ⁇ , -N(R 2 ⁇ ) 2 , -CON(R 2 ⁇ ) 2 , -COOR 2 ⁇ , straight chained or branched C ⁇ -C 7 alkyl, straight chained or branched C
- polyfluoroalkyl straight chained or branched C 2 -C 7 alkenyl, straight chained or branched C-C? alkynyl, C 5 -C? cycloalkenyl, -(CH 2 ) m -Z, or (CH 2 ) n -0- (CH 2 ) m -CH 3 ;
- R 18 is straight chained or branched C ⁇ -C 6 alkyl, - (CH 2 ) m -Z, or (CH 2 ) q -0-(CH 2 ) m -CH 3 ;
- each R ⁇ 9 is independently H, or straight chained or branched C ⁇ -C ⁇ alkyl
- each R 20 is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C? alkenyl or alkynyl; C 3 - C ?
- each R 2i is independently -H; straight chained or branched C ⁇ -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C 2 -C? alkenyl or alkynyl; C 3 - C 7 cycloalkyl, C 5 -C 6 cycloalkenyl, aryl or aryl (Ci- C 6 ) alkyl;
- each m is an integer from 0 to 4 inclusive;
- n is an integer from 1 to 4 inclusive; wherein p is an integer from 0 to 2 inclusive;
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09010003A EP2140864A3 (fr) | 2001-01-31 | 2002-01-31 | Utilisation des antagonistes de récepteur GAL3 pour le traitement de la dépression et/ou de l'anxiété et composés utiles dans ces procédés |
EP09010004A EP2140862A3 (fr) | 2001-01-31 | 2002-01-31 | Utilisation d'antagonistes du recepteur GAL3 dans le traitement de la dépression et/ou de l'anxiété et composés utiles dans de telles méthodes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77534101A | 2001-01-31 | 2001-01-31 | |
US775341 | 2001-01-31 | ||
PCT/US2002/004608 WO2002060392A2 (fr) | 2001-01-31 | 2002-01-31 | Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09010004A Division EP2140862A3 (fr) | 2001-01-31 | 2002-01-31 | Utilisation d'antagonistes du recepteur GAL3 dans le traitement de la dépression et/ou de l'anxiété et composés utiles dans de telles méthodes |
EP09010003A Division EP2140864A3 (fr) | 2001-01-31 | 2002-01-31 | Utilisation des antagonistes de récepteur GAL3 pour le traitement de la dépression et/ou de l'anxiété et composés utiles dans ces procédés |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1363638A2 true EP1363638A2 (fr) | 2003-11-26 |
EP1363638A4 EP1363638A4 (fr) | 2010-01-06 |
Family
ID=25104097
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02714918A Withdrawn EP1363638A4 (fr) | 2001-01-31 | 2002-01-31 | Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes |
EP09010003A Withdrawn EP2140864A3 (fr) | 2001-01-31 | 2002-01-31 | Utilisation des antagonistes de récepteur GAL3 pour le traitement de la dépression et/ou de l'anxiété et composés utiles dans ces procédés |
EP09010004A Withdrawn EP2140862A3 (fr) | 2001-01-31 | 2002-01-31 | Utilisation d'antagonistes du recepteur GAL3 dans le traitement de la dépression et/ou de l'anxiété et composés utiles dans de telles méthodes |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09010003A Withdrawn EP2140864A3 (fr) | 2001-01-31 | 2002-01-31 | Utilisation des antagonistes de récepteur GAL3 pour le traitement de la dépression et/ou de l'anxiété et composés utiles dans ces procédés |
EP09010004A Withdrawn EP2140862A3 (fr) | 2001-01-31 | 2002-01-31 | Utilisation d'antagonistes du recepteur GAL3 dans le traitement de la dépression et/ou de l'anxiété et composés utiles dans de telles méthodes |
Country Status (22)
Country | Link |
---|---|
EP (3) | EP1363638A4 (fr) |
JP (3) | JP4739650B2 (fr) |
KR (1) | KR20040041092A (fr) |
CN (2) | CN100446767C (fr) |
AU (2) | AU2002247149B2 (fr) |
BG (1) | BG108114A (fr) |
BR (1) | BR0206844A (fr) |
CA (3) | CA2671776C (fr) |
CZ (1) | CZ20032341A3 (fr) |
EA (1) | EA006486B1 (fr) |
HR (1) | HRP20030608A2 (fr) |
HU (1) | HUP0401858A3 (fr) |
IL (2) | IL157102A0 (fr) |
IS (1) | IS6880A (fr) |
MX (1) | MXPA03006812A (fr) |
NO (1) | NO20033388L (fr) |
NZ (1) | NZ527163A (fr) |
PL (1) | PL369270A1 (fr) |
SK (1) | SK9562003A3 (fr) |
UA (1) | UA74421C2 (fr) |
YU (1) | YU60803A (fr) |
ZA (1) | ZA200305686B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100446767C (zh) * | 2001-01-31 | 2008-12-31 | H.隆德贝克有限公司 | Gal3受体拮抗剂在制备治疗抑郁和/或焦虑药物中的应用及在这种方法中有用的化合物 |
AU2003203148A1 (en) * | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
CN101973925B (zh) * | 2010-10-15 | 2012-03-28 | 中国药科大学 | 具有抗炎活性的2-吲哚酮类化合物、其制备方法及医药用途 |
WO2015054317A1 (fr) * | 2013-10-07 | 2015-04-16 | Kadmon Corporation, Llc | Inhibiteurs de la rho kinase |
BR112019013571A2 (pt) * | 2016-12-29 | 2020-01-07 | Minoryx Therapeutics S.L. | Compostos heteroarila e seu uso |
WO2020160156A2 (fr) * | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anticorps anti-gal3 et leurs utilisations |
CN113317221B (zh) * | 2021-06-18 | 2023-01-31 | 青岛百宜电器有限公司 | 自动梳毛机 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS50140441A (fr) * | 1974-04-23 | 1975-11-11 | ||
GB1477349A (en) * | 1975-09-24 | 1977-06-22 | Ciba Geigy Ag | Azo pigments |
MA18829A1 (fr) * | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
US4946956A (en) * | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
JPH02300264A (ja) * | 1989-05-16 | 1990-12-12 | Fuji Photo Film Co Ltd | アミノピリミジンアゾメチン色素とその製造方法 |
JPH02308248A (ja) * | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
HUT64323A (en) * | 1992-06-09 | 1993-12-28 | Richter Gedeon Vegyeszet | Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives |
DK69693D0 (da) * | 1993-06-14 | 1993-06-14 | Neurosearch As | Farven lilla |
CN1104418C (zh) * | 1994-06-15 | 2003-04-02 | 大塚制药株式会社 | 苯并杂环衍生物 |
DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
DK0765858T3 (da) * | 1995-04-12 | 2000-05-01 | Ueno Seiyaku Oyo Kenkyujo Kk | Naphtholderivater og fremgangsmåder til fremstilling af samme |
CZ378497A3 (cs) * | 1995-06-02 | 1998-04-15 | Synthelabo | Deriváty oxazolidinonu, způsob jejich přípravy a jejich terapeutické použití |
WO1998055457A1 (fr) * | 1995-10-13 | 1998-12-10 | Transitions Optical, Inc. | Naphtopyrans substitues |
FR2741072B1 (fr) * | 1995-11-09 | 1997-12-12 | Synthelabo | Derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique |
US6329197B2 (en) | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
DE69804273T2 (de) * | 1997-07-18 | 2002-10-31 | Hoffmann La Roche | 5h-Thiazolo[3,2-a]pyrimidinderivate |
JPH11158073A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
CN1240210A (zh) * | 1998-04-17 | 2000-01-05 | 伊莱利利公司 | 取代的三环化合物 |
CA2334186A1 (fr) * | 1998-06-05 | 1999-12-09 | Regent Court Technologies | Inhibiteurs de monoamine oxydase (mao) et leurs utilisations |
PE20001236A1 (es) * | 1998-11-13 | 2000-11-10 | Lilly Co Eli | Moduladores del receptor de aminoacidos excitadores |
NZ515894A (en) * | 1999-06-02 | 2003-09-26 | Nps Pharma Inc | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
WO2000076980A1 (fr) * | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives heterocycliques azotes ou leurs sels |
CA2394727A1 (fr) * | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Composes de pyrimidine et de triazine presentant une activite inhibant la kinase |
CN100446767C (zh) * | 2001-01-31 | 2008-12-31 | H.隆德贝克有限公司 | Gal3受体拮抗剂在制备治疗抑郁和/或焦虑药物中的应用及在这种方法中有用的化合物 |
-
2002
- 2002-01-31 CN CNB028077547A patent/CN100446767C/zh not_active Expired - Fee Related
- 2002-01-31 KR KR10-2003-7010147A patent/KR20040041092A/ko not_active Application Discontinuation
- 2002-01-31 CA CA2671776A patent/CA2671776C/fr not_active Expired - Fee Related
- 2002-01-31 UA UA2003088106A patent/UA74421C2/uk unknown
- 2002-01-31 SK SK956-2003A patent/SK9562003A3/sk unknown
- 2002-01-31 NZ NZ527163A patent/NZ527163A/en unknown
- 2002-01-31 CZ CZ20032341A patent/CZ20032341A3/cs unknown
- 2002-01-31 EP EP02714918A patent/EP1363638A4/fr not_active Withdrawn
- 2002-01-31 HU HU0401858A patent/HUP0401858A3/hu unknown
- 2002-01-31 CA CA002672805A patent/CA2672805A1/fr not_active Abandoned
- 2002-01-31 YU YU60803A patent/YU60803A/sh unknown
- 2002-01-31 AU AU2002247149A patent/AU2002247149B2/en not_active Ceased
- 2002-01-31 CA CA2438582A patent/CA2438582C/fr not_active Expired - Fee Related
- 2002-01-31 JP JP2002560588A patent/JP4739650B2/ja not_active Expired - Fee Related
- 2002-01-31 EP EP09010003A patent/EP2140864A3/fr not_active Withdrawn
- 2002-01-31 EA EA200300850A patent/EA006486B1/ru not_active IP Right Cessation
- 2002-01-31 PL PL02369270A patent/PL369270A1/xx not_active Application Discontinuation
- 2002-01-31 MX MXPA03006812A patent/MXPA03006812A/es active IP Right Grant
- 2002-01-31 BR BR0206844-3A patent/BR0206844A/pt not_active IP Right Cessation
- 2002-01-31 CN CN200810170443XA patent/CN101406469B/zh not_active Expired - Fee Related
- 2002-01-31 EP EP09010004A patent/EP2140862A3/fr not_active Withdrawn
- 2002-01-31 IL IL15710202A patent/IL157102A0/xx unknown
-
2003
- 2003-07-21 IS IS6880A patent/IS6880A/is unknown
- 2003-07-23 ZA ZA200305686A patent/ZA200305686B/en unknown
- 2003-07-28 HR HR20030608A patent/HRP20030608A2/hr not_active Application Discontinuation
- 2003-07-29 NO NO20033388A patent/NO20033388L/no unknown
- 2003-08-20 BG BG108114A patent/BG108114A/bg unknown
-
2008
- 2008-01-25 AU AU2008200385A patent/AU2008200385B2/en not_active Ceased
-
2009
- 2009-02-19 JP JP2009037247A patent/JP2009173657A/ja active Pending
- 2009-05-14 IL IL198759A patent/IL198759A/en not_active IP Right Cessation
- 2009-07-24 JP JP2009172594A patent/JP2010006813A/ja not_active Withdrawn
Non-Patent Citations (12)
Title |
---|
ABDEL-RAHMAN, R. M. ET AL: "Synthesis of some 1,2,4-triazino[4,3-a]indole derivatives" JOURNAL OF THE INDIAN CHEMICAL SOCIETY ( 1991 ), 68(11), 621-4 CODEN: JICSAH; ISSN: 0019-4522, 1991, XP008115404 * |
BAIOCCHI L ET AL: "SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF SOME NEW INDOLOÄ2,1-BÜQUINAZOLIN-6(12H)ONES" FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 48, no. 4, 1 January 1993 (1993-01-01), pages 487-501, XP009063144 ISSN: 0014-827X * |
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OTOMASU, HIROTAKA ET AL: "Spiro[indoline-3,2'-thiazolidine]-2,4'-di ones" XP002557734 retrieved from STN Database accession no. 1976:432991 & JP 50 140441 A (KOHJIN CO., LTD., JAPAN) 11 November 1975 (1975-11-11) -& DATABASE REGISTRY 16 November 1984 (1984-11-16), XP002557735 retrieved from STN Database accession no. 59618-76-7 * |
DATABASE REGISTRY 17 November 2000 (2000-11-17), XP002557739 retrieved from STN Database accession no. 303149-06-6 -& DATABASE REGISTRY 22 November 2000 (2000-11-22), XP002557740 retrieved from STN Database accession no. 303984-51-2 -& DATABASE REGISTRY 17 November 2000 (2000-11-17), XP002557741 retrieved from STN Database accession no. 303149-14-6 -& DATABASE REGISTRY 17 November 2000 (2000-11-17), XP002557742 retrieved from STN Database accession no. 303149-12-4 * |
DATABASE REGISTRY 18 December 2000 (2000-12-18), XP002557736 retrieved from STN Database accession no. 309271-04-3 * |
DATABASE REGISTRY 19 December 2000 (2000-12-19), XP002557737 retrieved from STN Database accession no. 309744-91-0 * |
JOSHI, K. C. ET AL: "Possible psychopharmacological agents. X. Synthesis of some fluorine-containing indole-2,3-dione derivatives" JOURNAL FUER PRAKTISCHE CHEMIE (LEIPZIG) ( 1980 ), 322(2), 314-20 CODEN: JPCEAO; ISSN: 0021-8383, 1980, XP002557733 * |
KNOTZ, FLORIAN: "Preparation of antiviral and antimicrobial substances. 2. Acyl hydrazones and thiosemicarbazones of 1-isatin acetic acid derivatives" SCIENTIA PHARMACEUTICA ( 1970 ), 38(3), 163-72 CODEN: SCPHA4; ISSN: 0036-8709, 1970, XP008115405 * |
See also references of WO02060392A2 * |
SEN GUPTA A K ET AL: "Synthesis of indole derivatives as potential biodynamic agents: Part II: 1,5-Disubstituted 3-(5-aryl-1,3,4-oxadiazol-2-yl)-iminoindol in-2 ones as possible antibacterial and CNS active agents" CURRENT SCIENCE, INDIAN ACADEMY OF SCIENCES, IN, vol. 51, no. 23, 5 December 1982 (1982-12-05), pages 1100-1103, XP008115354 ISSN: 0011-3891 -& DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SEN GUPTA, A. K. ET AL: "Synthesis of indole derivatives as potential biodynamic agents: Part II: 1,5-Disubstituted 3-(5-aryl-1,3,4-oxadiazol-2-yl)-iminoindol in-2-ones as possible antibacterial and CNS active agents" XP002557738 retrieved from STN Database accession no. 1983:83236 & CURRENT SCIENCE , 51(23), 1100-3 CODEN: CUSCAM; ISSN: 0011-3891, 1982, * |
VARMA, RAJENDRA S. ET AL: "Potential biologically active agents. Part XLIII. Synthesis of substituted 2-phenylbenzoxazoles as CNS active agents" INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY ( 1985 ), 24B(3), 280-5 CODEN: IJSBDB; ISSN: 0376-4699, 1985, XP008115349 * |
ZAM A ET AL: "Synthesis and pharmacological activities of Mannich bases using indole-2,3-dione/3-phenylimino-2-indolinon e as amine moiety" JOURNAL OF THE INSTITUTION OF CHEMISTS (INDIA), CALCUTTA, IN, vol. 68, no. 4, 1 January 1996 (1996-01-01), pages 114-116, XP008115350 ISSN: 0020-3254 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7465750B2 (en) | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | |
WO2002060392A2 (fr) | Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes | |
US8198313B2 (en) | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
AU2008200385B2 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
US7220775B2 (en) | Compound useful for the treatment of neuropathic pain | |
AU2002247149A1 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
US20050148635A1 (en) | 3-imino-2-indolones for the treatment of depression and/or anxiety | |
US20040110821A1 (en) | GAL3 receptor antagonists for the treatment of affective disorders | |
WO2004014307A2 (fr) | Antagonistes de gal3 destines au traitement de douleurs neuropathiques | |
WO2004014376A1 (fr) | Antagonistes du recepteur gal3 pour le traitement des troubles affectifs | |
JP5688918B2 (ja) | 医薬組成物 | |
US6936607B2 (en) | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | |
AU2008200380A1 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
WO2004014854A1 (fr) | 3-imino-2-indolones pour traiter la depression et/ou l'anxiete | |
WO2004034967A2 (fr) | 2,4,6-triaminopyrimidines utilisees dans le traitement de la depression et/ou de l'anxiete |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030901 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NOBLE, STEWART Inventor name: LIM, KITAE Inventor name: LAGU, BHARAT Inventor name: JIMENEZ, HERMO Inventor name: CHEN, HEIDI Inventor name: PACKIARAJAN, MATHIVANAN Inventor name: WETZEL, JOHN M. Inventor name: TALISMAN, IAN JAMIE Inventor name: BOTEJU, LAKMAL W. Inventor name: KONKEL, MICHAEL Inventor name: BLACKBURN, THOMAS P. |
|
RTI1 | Title (correction) |
Free format text: USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1061190 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: H. LUNDBECK A/S |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20091208 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/24 20060101ALI20091130BHEP Ipc: C07D 417/12 20060101ALI20091130BHEP Ipc: C07D 413/06 20060101ALI20091130BHEP Ipc: C07D 413/04 20060101ALI20091130BHEP Ipc: C07D 409/14 20060101ALI20091130BHEP Ipc: C07D 409/12 20060101ALI20091130BHEP Ipc: C07D 409/06 20060101ALI20091130BHEP Ipc: C07D 409/04 20060101ALI20091130BHEP Ipc: C07D 405/14 20060101ALI20091130BHEP Ipc: C07D 405/12 20060101ALI20091130BHEP Ipc: C07D 403/12 20060101ALI20091130BHEP Ipc: C07D 403/04 20060101ALI20091130BHEP Ipc: C07D 401/14 20060101ALI20091130BHEP Ipc: C07D 401/12 20060101ALI20091130BHEP Ipc: C07D 401/06 20060101ALI20091130BHEP Ipc: C07D 401/04 20060101ALI20091130BHEP Ipc: C07D 239/50 20060101ALI20091130BHEP Ipc: C07D 209/40 20060101ALI20091130BHEP Ipc: A61K 31/506 20060101ALI20091130BHEP Ipc: A61K 31/407 20060101AFI20091130BHEP |
|
17Q | First examination report despatched |
Effective date: 20100610 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1061190 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140715 |